|
Market Closed -
NYSE
16:03:33 2026-09-02 EDT
|
5-day change | 1st Jan Change | ||
| 209.91 USD | +1.44% |
|
-2.81% | -8.30% |
| 09-01 | HSBC Adjusts Price Target on Danaher to $250 From $230, Maintains Buy Rating | MT |
| 08-24 | Cytek Biosciences Shares Drop After Jury Says It Owes $56 Million in Damages | DJ |
Company Valuation: Danaher Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 235,103 | 193,216 | 170,943 | 165,798 | 161,698 | 145,469 | - | - |
| Change | - | -17.82% | -11.53% | -3.01% | -2.47% | -10.04% | - | - |
| Enterprise Value (EV) 1 | 254,693 | 206,898 | 183,481 | 179,725 | 175,501 | 165,819 | 161,208 | 157,108 |
| Change | - | -18.77% | -11.32% | -2.05% | -2.35% | -5.52% | -2.78% | -2.54% |
| P/E | 38.2x | 27.5x | 36.3x | 43.4x | 45.3x | 34.9x | 28.6x | 25.9x |
| PBR | 5.21x | 3.86x | 3.2x | 3.33x | 3.08x | 2.75x | 2.54x | 2.35x |
| PEG | - | 2.3x | -1.1x | -2.5x | -9.98x | 2x | 1.3x | 2.5x |
| Capitalization / Revenue | 7.98x | 6.14x | 7.16x | 6.94x | 6.58x | 5.52x | 5.11x | 4.78x |
| EV / Revenue | 8.65x | 6.57x | 7.68x | 7.53x | 7.14x | 6.29x | 5.66x | 5.16x |
| EV / EBITDA | 26.4x | 19x | 24.4x | 24.9x | 22.8x | 20x | 17.6x | 15.8x |
| EV / EBIT | 34.1x | 23.8x | 26.8x | 26.1x | 25.3x | 22x | 19.4x | 17.4x |
| EV / FCF | 36.1x | 28.1x | 31.7x | 33.9x | 33.2x | 30.1x | 25.2x | 22.1x |
| FCF Yield | 2.77% | 3.57% | 3.15% | 2.95% | 3.02% | 3.33% | 3.97% | 4.52% |
| Dividend per Share 2 | 0.84 | 1 | 1.05 | 1.08 | 1.28 | 1.423 | 1.58 | 1.697 |
| Rate of return | 0.26% | 0.38% | 0.45% | 0.47% | 0.56% | 0.69% | 0.76% | 0.82% |
| EPS 2 | 8.61 | 9.66 | 6.38 | 5.29 | 5.05 | 5.928 | 7.238 | 7.99 |
| Distribution rate | 9.76% | 10.4% | 16.5% | 20.4% | 25.3% | 24% | 21.8% | 21.2% |
| Net sales 1 | 29,453 | 31,471 | 23,890 | 23,875 | 24,568 | 26,345 | 28,464 | 30,425 |
| EBITDA 1 | 9,633 | 10,910 | 7,530 | 7,215 | 7,689 | 8,307 | 9,142 | 9,966 |
| EBIT 1 | 7,465 | 8,688 | 6,855 | 6,897 | 6,939 | 7,545 | 8,312 | 9,026 |
| Net income 1 | 6,269 | 7,103 | 4,743 | 3,899 | 3,614 | 4,204 | 5,146 | 5,460 |
| Net Debt 1 | 19,590 | 13,682 | 12,538 | 13,927 | 13,803 | 20,350 | 15,739 | 11,640 |
| Reference price 2 | 329.01 | 265.42 | 231.34 | 229.55 | 228.92 | 206.93 | 206.93 | 206.93 |
| Nbr of stocks (in thousands) | 714,577 | 727,963 | 738,927 | 722,275 | 706,350 | 702,986 | - | - |
| Announcement Date | 1/27/22 | 1/24/23 | 1/30/24 | 1/29/25 | 1/28/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 34.9x | 6.29x | 19.96x | 0.69% | 145B | |
| 29.91x | 5.32x | 20.4x | 0.31% | 222B | |
| 40.5x | 10.52x | 23.26x | -.--% | 130B | |
| 17.95x | 3.67x | 11.91x | -.--% | 69.68B | |
| 35.86x | 7.2x | 22.78x | -.--% | 52.3B | |
| 19.47x | 2.34x | 11.7x | 2.62% | 50.71B | |
| 29.2x | 5.76x | 19.58x | 0.69% | 42.28B | |
| 71.05x | 6.79x | 20.67x | -.--% | 39.87B | |
| 20.08x | 5.57x | 14.39x | 1.15% | 33.37B | |
| 41.85x | 6.82x | 24.05x | -.--% | 31.28B | |
| Average | 34.08x | 6.03x | 18.87x | 0.55% | 81.74B | |
| Weighted average by Cap. | 33.23x | 6.28x | 19.53x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DHR Stock
- Valuation Danaher Corporation
Select your edition
All financial news and data tailored to specific country editions
